malaria
teas
human
popul
long
time
present
sever
class
antimalari
drug
avail
market
issu
toxic
lower
efficaci
resist
malari
parasit
decreas
overal
therapeut
indic
thu
search
new
promis
antimalari
continu
howev
battl
malaria
far
ferroquin
deriv
chloroquin
antimalari
properti
success
chloroquin
deriv
ferroquin
also
deriv
shown
promis
potenti
antimalari
clinic
interest
present
much
research
dedic
develop
ferroquin
deriv
safe
altern
antimalari
chemotherapi
present
articl
describ
structur
chemic
biolog
featur
ferroquin
sever
class
ferroquin
deriv
includ
hydroxyferroquin
trioxaferroquin
chloroquinebridg
ferrocenophan
thiosemicarbazon
deriv
ferrocen
dual
conjug
deriv
other
discuss
besid
mechan
action
ferroquin
discuss
care
observ
made
pharmacolog
signific
ferroquin
deriv
better
equal
therapeut
effect
chloroquin
ferroquin
brief
discuss
toxic
ferroquin
deriv
made
final
effort
made
discuss
current
challeng
futur
perspect
ferroquinebas
antimalari
drug
develop
malaria
mosquitoborn
diseas
human
be
caus
parasit
protozoan
plasmodium
genu
parasit
infect
recogn
one
major
caus
death
third
world
countri
plasmodium
falciparum
plasmodium
vivax
plasmodium
oval
plasmodium
malaria
four
notori
speci
protozo
parasit
caus
malaria
human
p
falciparum
p
vivax
account
malari
infect
worldwid
among
variou
speci
plasmodium
p
falciparum
lethal
one
caus
virul
form
human
malaria
annual
p
falciparum
known
caus
million
infect
million
death
gener
malaria
associ
symptom
fatigu
fever
headach
vomit
sever
case
may
caus
yellow
skin
seizur
coma
even
death
malaria
report
infect
human
popul
year
first
evid
plasmodium
report
fossil
culex
mosquito
piec
amber
almost
million
year
old
present
sever
drug
chloroquin
cq
amodiaquin
pyrimethamin
proguanil
mefloquin
atovaquon
primaquin
etc
fig
avail
market
treatment
malaria
main
target
antimalari
drug
erythrocyt
stage
malari
infect
last
two
decad
resist
p
falciparum
strain
cq
emerg
antifol
combin
sulfadoxinepyrimethamin
led
artemisinin
combin
therapi
act
act
worldwid
treatment
uncompl
malaria
howev
recent
fear
onset
artemisinin
resist
cambodia
stimul
develop
new
antidot
malaria
ferroquin
fq
design
biot
cowork
univers
lill
later
success
synthes
incorpor
ferrocen
unit
basic
skeleton
cq
fig
fq
found
remark
effect
cqresist
p
falciparum
observ
immunotox
effect
infect
young
rat
act
haematin
caus
inhibit
hemozoin
format
interest
antimalari
properti
fq
stimul
extens
develop
analogu
hope
increas
efficaci
lower
side
effect
abil
overcom
resist
malari
parasit
present
sever
class
fq
deriv
analogu
prepar
test
antimalari
properti
interest
result
obtain
sever
instanc
literatur
updat
indic
increas
interest
develop
antimalari
drug
last
coupl
decad
exhaust
search
literatur
scifind
pubm
show
fq
deriv
extens
investig
antimalari
agent
hundr
research
paper
appear
antimalari
properti
fq
deriv
interest
result
analysi
number
public
fq
deriv
antimalari
agent
indic
steadili
grow
interest
research
topic
period
divid
three
interv
viz
graph
plot
shown
fig
clear
figur
number
research
report
increas
consider
look
literatur
indic
review
paper
appear
fq
antimalari
agent
besid
book
chapter
biot
et
al
appear
antimalari
properti
fq
howev
relev
review
appear
topic
therefor
updat
review
recent
advanc
field
larg
miss
thu
thought
worthwhil
address
recent
advanc
develop
fq
deriv
antimalari
clinic
interest
present
review
highlight
epidemiolog
malaria
global
concern
need
develop
better
fq
deriv
besid
chemic
biolog
featur
fq
discuss
addit
mechan
action
fq
malari
parasit
describ
care
observ
pharmacolog
signific
fq
deriv
better
equal
therapeut
effect
cq
fq
present
addit
issu
toxic
ferroquin
deriv
outlin
final
current
challeng
futur
perspect
fqbase
antimalari
drug
develop
discuss
review
updat
refer
materi
signific
help
research
antimalari
drug
develop
often
malaria
character
symptom
fever
clinic
appear
malaria
attribut
erythrocyt
phase
parasit
develop
initi
malari
symptom
follow
prepat
period
constitut
primari
attack
diseas
progress
relaps
symptom
regular
interv
h
call
short
term
relaps
besid
long
term
relaps
day
also
report
malari
infect
p
vivax
p
oval
involv
relaps
due
reactiv
hypnozoit
liver
falciparum
malaria
infect
relaps
refer
recrudesc
recrudesc
thought
due
persist
blood
infect
prepat
period
infect
individu
may
characterist
symptom
end
erythrocyt
schizogoni
phase
rbc
ruptur
matur
schizont
releas
merozoit
blood
thu
infect
rbc
grow
parasit
gradual
consum
degrad
intracellular
protein
specif
haemoglobin
result
malari
pigment
format
haemolysi
infect
rbc
transport
properti
rbc
membran
alter
becom
spheric
less
deform
ruptur
rbc
releas
sever
factor
toxin
red
cell
membran
lipid
glycosyl
phosphatidyl
inositol
anchor
parasit
membran
protein
directli
initi
releas
cytokin
tumour
necrosi
factor
tnf
macrophag
lead
chill
highgrad
fever
occur
h
correspond
erythrocyt
cycl
p
falciparum
malaria
infect
rbc
develop
sticki
protrus
cell
membran
help
adhes
clump
besid
rbc
may
also
stick
wall
minut
capillari
venul
arteriol
block
blood
flow
process
may
lead
damag
vital
organ
includ
kidney
brain
liver
lung
gastrointestin
tract
seriou
complic
falciparum
malaria
cerebr
malaria
wherein
blockag
cerebr
microcircul
parasit
rbc
seem
basic
underli
defect
howev
complet
obstruct
blood
flow
survivor
perman
neurolog
deficit
p
vivax
p
oval
infect
gener
benign
rare
complic
signific
morbid
mortal
sporozoit
p
vivax
p
oval
hibern
liver
hibern
hypnozoit
reactiv
lead
relaps
clinic
ill
month
malaria
global
epidem
diseas
known
china
mesopotamia
egypt
sinc
bc
respect
promin
malari
infect
grew
due
advanc
agricultur
migrat
human
popul
colon
new
land
present
malaria
one
major
caus
human
miseri
due
increas
morbid
mortal
halt
intellectu
econom
growth
malaria
affect
approxim
million
peopl
annual
death
death
occur
children
year
age
malari
epidemiolog
report
indic
approxim
million
malari
case
death
make
malaria
one
import
human
diseas
parasit
origin
five
plasmodium
speci
infect
human
be
p
falciparum
sever
caus
death
approxim
billion
peopl
high
risk
billion
peopl
get
exposur
malari
infect
everi
year
global
world
health
organ
indic
million
peopl
symptomat
malaria
addit
death
death
occur
children
africa
one
child
die
everi
minut
overal
malaria
endem
diseas
affect
popul
world
strateg
incorpor
ferrocenyl
moieti
structur
wellknown
antimalari
agent
first
tri
still
yet
structur
design
investig
continu
much
surpris
obtain
disappoint
result
ferrocenyl
incorpor
mefloquin
quinin
artemisinin
atovaquon
antimalari
activ
newli
graft
molecul
either
inferior
equal
parent
drug
molecul
failur
ferrocenyl
deriv
mefloquin
quinin
attribut
instabl
acid
condit
late
end
centuri
ferrocenyl
compound
fluoroquinolon
obtain
via
esterif
carboxyl
group
ciprofloxacin
along
addit
ferrocenyl
moieti
compound
produc
approach
consider
activ
ciprofloxacin
esterif
assum
enhanc
activ
along
complementari
efficaci
enhanc
due
insert
ferrocen
core
derivat
cq
final
gave
birth
potenti
effect
antimalari
agent
sever
graft
experi
indic
simpl
addit
product
basic
cq
ferrocen
carboxyl
acid
form
via
salt
bridg
display
poor
antimalari
activ
probabl
due
antagon
two
compound
addit
condens
ferrocen
fig
endocycl
nitrogen
also
decreas
activ
respect
cq
monoferrocenyl
deriv
wherein
ferrocenyl
group
link
termin
nitrogen
along
modul
later
chain
size
also
could
result
activ
enhanc
compar
cq
besid
molecul
demonstr
high
risk
crossresist
cq
particularli
inconsist
result
obtain
diferrocenyl
conjug
probabl
instabl
experiment
condit
surprisingli
ferrocen
insert
later
chain
cq
result
format
compound
high
activ
cqsuscept
cqresist
strain
p
falciparum
activ
independ
substitut
termin
nitrogen
one
main
determin
antimalari
activ
compound
toward
cqresist
parasit
posit
ferrocen
moieti
within
later
chain
fq
activ
compound
class
addit
studi
carri
find
molecul
better
activ
reason
cost
industri
product
howev
effort
fail
find
possibl
competitor
fq
vitro
vivo
experi
explor
fq
potenti
antimalari
agent
led
entri
preclin
phase
develop
sanofiaventi
howev
respons
regul
reduc
emerg
parasit
resist
fq
use
combin
therapi
artesun
subsequ
develop
fq
continu
entri
clinic
phase
ii
studi
adult
human
late
fq
known
first
organometal
drug
ferrocenyl
group
coval
skirt
basic
alkylamin
fig
bear
planar
chiral
due
presenc
substitut
ferrocen
moieti
fig
b
biolog
experi
fq
often
use
racem
mixtur
dramat
differ
activ
pure
enantiom
fq
human
rodent
parasit
almost
equal
cytotox
observ
two
enantiom
fact
allow
develop
racem
mixtur
fq
antimalari
drug
strong
intramolecular
hydrogen
bond
length
amin
n
amin
n
fig
document
stabil
structur
neutral
fq
solidst
solut
organ
solvent
chloroform
comparison
flexibl
later
side
chain
cq
intramolecular
hydrogen
bond
stronger
fq
sever
studi
carri
demonstr
effect
intramolecular
hydrogen
bond
antimalari
activ
fq
biot
et
al
replac
hydrogen
atom
anilin
n
fq
methyl
group
produc
fqme
observ
fqme
exhibit
similar
physicochem
properti
fq
also
demonstr
abil
inhibit
bhaematin
format
howev
fqme
significantli
less
activ
cqsuscept
cqresist
strain
thu
hydrogen
bond
interact
later
side
chain
fq
suggest
contribut
antimalari
activ
interact
help
maintain
particular
geometr
ident
molecul
propos
part
molecul
modifi
isoster
insert
ferrocenyl
moieti
instead
alkyl
chain
interact
receptor
howev
properli
orient
function
molecul
besid
ferrocen
moieti
tangl
lipid
structur
enabl
drug
drip
transport
system
involv
resist
help
concentr
drug
proper
site
inhibit
hemozoin
format
fq
share
sever
properti
parent
antimalari
cq
cq
act
accumul
digest
vacuol
parasit
consequ
prevent
crystal
toxic
heme
hemozoin
result
membran
damag
death
parasit
cq
complex
haematin
solut
inhibit
bhaematin
format
similar
cq
fq
natur
weak
base
abil
accumul
digest
vacuol
parasit
howev
pka
fq
lower
compar
cq
therefor
might
affect
properti
cq
interestingli
fq
also
form
complex
haematin
addit
inhibit
haematin
crystal
bhaematin
ic
versu
cq
moreov
fq
report
produc
signific
amount
hydroxyl
radic
digest
vacuol
malari
parasit
acid
ph
presenc
h
hydroxi
free
radic
known
damag
parasit
ration
drug
develop
base
molecular
structur
chloroquin
foster
develop
sever
ferrocen
base
molecul
howev
among
ferrocenyl
chloroquin
deriv
fq
activ
deriv
vitro
vivo
investig
earli
day
develop
consid
lead
compound
one
interest
properti
fq
abil
overcom
cqresist
problem
properti
enough
control
p
falciparum
princip
caus
agent
malaria
fq
test
vitro
differ
laboratori
p
falciparum
strain
eight
set
field
isol
total
collect
gabon
seneg
cambodia
thailand
sever
test
field
isol
differ
geograph
region
world
minor
cross
respons
cq
observ
howev
observ
cross
respons
weak
thought
clinic
import
crossresist
drug
moreov
correl
cq
fq
respons
use
standard
initi
parasitaemia
assay
vivo
investig
plasmodium
vinckei
antagonist
effect
observ
fq
artesun
surviv
time
infect
mice
increas
treatment
combin
two
drug
long
et
al
perform
vivo
investig
differ
murin
plasmodium
speci
observ
cur
dose
fq
mgkgd
day
irrespect
suscept
strain
cq
administr
strategi
demonstr
good
avail
power
activ
drug
studi
effect
naiv
anim
respons
plasmodium
infect
host
indic
two
advantag
fq
cq
first
one
rapid
efficaci
blood
parasit
decreas
tcell
involv
express
suscept
experiment
malaria
infect
thu
decreas
number
cell
would
help
express
protect
immun
second
advantag
potenti
maintain
prolifer
abil
spleen
cell
repli
differ
mitogen
thu
account
absenc
notic
immunotox
rat
along
vitro
efficaci
cqresist
strain
fq
suggest
effect
altern
treatment
p
falciparum
interestingli
result
vitro
test
field
isol
vivo
investig
rodent
model
reveal
potenti
resist
fq
depend
gene
polymorph
involv
cq
resist
basic
observ
cambodian
isol
extend
fifteen
p
falciparum
laboratori
strain
four
gene
current
involv
drug
resist
pfcrt
pfmrp
addit
pressur
experi
conduct
obtain
fqresist
p
falciparum
rodent
malaria
parasit
found
fitcost
fq
resist
extrem
high
persist
parasit
exhibit
reduc
vital
resist
observ
rodent
malari
parasit
genet
integr
wellknown
fact
basic
lipophil
fq
consider
differ
cq
howev
lipophil
fq
approach
cq
log
respect
former
proton
food
vacuol
ph
mark
differ
lipophil
observ
ph
log
fq
cq
respect
addit
fq
lower
pka
valu
cq
respect
differenti
pka
valu
determin
rel
concentr
micro
speci
vacuolar
ph
neutral
monoproton
fq
micro
speci
concentr
vacuolar
ph
cq
micro
speci
known
interact
haematin
enabl
convers
hemozoin
report
indic
fq
lipophil
cq
cytosol
ph
around
ph
fq
concentr
cq
accord
ph
affect
behaviour
fq
hypothes
fq
might
target
lipid
site
hemozoin
format
profici
molecular
structur
fq
contain
strong
intramolecular
hydrogen
bond
anilino
n
tertiari
amino
n
group
fig
result
sever
nmr
experi
shown
structur
fq
solut
low
dielectr
constant
lipid
environ
solid
phase
role
hydrogen
bond
antimalari
activ
fq
remain
subject
debat
time
flipflop
hydrogen
bond
open
conform
charg
fq
fold
conform
uncharg
fq
facilit
transport
water
hydrophob
membran
justifi
import
hydrogen
bond
molecular
structur
fq
bio
et
al
document
fq
analogu
methyl
group
place
hydrogen
atom
anilino
n
reduc
antimalari
activ
suscept
resist
strain
cq
despit
almost
unaffect
physicochem
properti
fq
fq
known
assum
notabl
conform
wherein
side
chain
stand
planar
quinolin
ring
bulki
ferrocenyl
moieti
project
outsid
molecular
structur
fq
flexibl
side
chain
reduc
due
rigid
ferrocen
core
lead
thermodynam
increas
entropi
increas
entropi
fq
assum
one
main
reason
cluster
lipid
membran
fq
enabl
favour
interact
owe
hydrophob
collaps
lipid
structur
membran
quinolin
ring
expos
water
similar
cq
fq
ensur
complex
format
haematin
aqueou
solut
log
k
addit
strongli
inhibit
bhaematin
format
cq
anoth
reason
high
antimalari
activ
fq
comparison
organ
drug
might
preferenti
local
fq
lipidewat
interfac
fq
might
help
prevent
convers
haematin
hemozoin
mainten
toxic
haematin
aqueou
environ
justifi
steadi
activ
fq
despit
resist
level
strain
oxid
condit
digest
vacuol
malari
parasit
fq
undergo
revers
oneelectron
redox
reaction
result
format
ferriquinium
salt
along
gener
hydroxyl
radic
shown
free
radic
gener
micromolar
rang
affect
stabil
fq
moreov
cluster
fq
close
membran
digest
vacuol
caus
gener
ro
lipid
peroxid
mechan
viz
inhibit
hemozoin
format
ro
gener
eventu
lead
death
malari
parasit
research
continu
make
effort
explor
mechan
fq
antimalari
agent
differ
malari
parasit
strain
vitro
vivo
recent
dubar
et
al
document
subcellular
map
gener
ho
p
falciparum
rbc
treat
fq
use
ratiometr
fluoresc
probe
oxid
damag
found
consist
damag
membran
digest
vacuol
lead
death
parasit
metallocen
moieti
prove
import
contributor
overal
mechan
action
fq
besid
fq
suppos
play
crucial
role
inhibit
merozoit
reinvas
studi
research
group
relat
breakdown
parasit
digest
vacuol
membran
fq
abil
gener
hydroxyl
radic
huge
interest
develop
antimalari
drug
base
fq
templat
initi
success
fq
antimalari
agent
sever
class
structur
divers
molecul
design
develop
hope
ensur
resist
free
death
malari
parasit
import
class
fq
deriv
discuss
follow
subsect
revel
strong
antimalari
effect
fq
cqresist
clone
field
isol
design
develop
hydroxyferroquin
deriv
thought
evolv
new
molecul
potenti
activ
p
falciparum
strain
biot
et
al
synthes
three
fq
deriv
fig
close
mimick
hydroxychloroquin
although
compound
less
activ
fq
display
inhibit
vitro
growth
p
falciparum
quit
higher
cq
ic
valu
strain
p
falciparum
comparison
cq
fq
given
tabl
interestingli
compound
also
exhibit
antivir
effect
select
toward
sever
acut
respiratori
syndrom
coronaviru
sarscov
infect
result
research
report
may
suggest
compound
interest
altern
fq
antimalari
therapi
would
highli
benefic
geograph
region
malaria
viral
infect
coexist
trioxaquin
class
hybrid
molecul
dual
mode
action
class
compound
contain
two
coval
link
pharmacophor
viz
hybrid
molecul
thought
possibl
altern
recent
grow
resist
artemisinin
interestingli
first
gener
trioxaquin
highli
activ
cqresist
strain
p
falciparum
due
success
hybrid
molecul
fame
treatment
malaria
neglect
tropic
diseas
becom
widespread
fq
may
also
seen
hybrid
molecul
wherein
ferrocenyl
moieti
insert
within
side
chain
cq
bellot
et
al
report
seri
trioxaferroquin
fig
potenti
antimalari
agent
two
cqresist
strain
tabl
chemic
report
trioxaferroquin
hybrid
molecul
moieti
coval
link
fq
trioxaferroquin
display
ic
valu
rang
nm
may
realiz
coval
link
quinolin
trioxaferrocen
via
ferrocen
significantli
boost
activ
fragment
despit
inact
cq
toward
strain
tabl
also
essenti
moieti
trioxaferroquin
antimalari
activ
case
cqresist
strain
highlight
compound
best
trioxaferroquin
ic
nm
respect
thu
investig
vivo
p
vinckei
petteri
parasit
erythrocyt
infect
mice
untreat
mice
surviv
time
day
four
day
period
mice
daili
given
oral
dosag
mgkgd
mgkgd
result
indic
parasitaemia
detect
level
day
four
even
mice
treat
mgkgday
indic
prompt
clearanc
parasit
number
mice
treat
day
time
period
treatment
mgkgd
respect
mean
surviv
time
mice
treat
mgkg
ca
day
recurr
day
therefor
trioxaferroquin
high
activ
quit
abl
clear
parasitaemia
detect
level
mice
treat
mgkg
howev
quit
import
note
cur
effect
recurr
achiev
dose
mg
kg
critic
evalu
report
indic
trioxaferroquin
novel
class
antiparasit
agent
profound
vivo
vitro
efficaci
howev
need
lower
dosag
complet
cure
obtain
purpos
new
molecul
base
templat
need
develop
investig
futur
sala
et
al
document
five
disubstitut
ferrocen
cq
deriv
wherein
termin
nitrogen
atom
cq
deriv
bridg
two
cyclopentadienyl
ring
ferrocen
fig
deriv
compar
correspond
monosubstitut
ferrocen
cq
analogu
fig
correspond
organ
fragment
fig
compound
activ
differ
strain
p
falciparum
includ
cqsensit
cqresist
cqresist
tabl
observ
bridg
disubstitut
ferrocenyl
compound
overcam
resist
activ
resist
strain
except
compound
compar
sensit
one
branch
methylen
spacer
profound
effect
activ
deriv
lost
activ
increas
branch
besid
presenc
intramolecular
hbond
determin
antiplasmodi
activ
compound
found
associ
haematin
howev
associ
import
forc
vitro
activ
balanc
lipophil
hydrophil
compound
determin
activ
addit
ferrocenyl
unit
larg
increas
lipophil
past
relat
improv
transport
drug
membran
calcul
partit
coeffici
log
p
valu
topolog
polar
surfac
area
tpsa
gave
best
balanc
compound
compact
size
conform
tabl
vitro
activ
p
falciparum
strain
respect
respect
cq
fq
ic
valu
indic
compound
better
activ
cq
balanc
lipophil
hydrophil
bridg
deriv
enabl
escap
mechan
resist
pathogen
thu
may
suppos
compound
would
benefit
due
slightli
hydrophil
natur
electroneg
area
avail
addit
intramolecular
hydrogenbond
interact
could
allow
flipflop
mechan
flipflop
mechan
assum
aid
accumul
fq
cross
membran
analysi
paramet
determin
antiplasmodi
activ
combin
silico
calcul
compound
may
help
design
fq
analogu
adjust
lipophilicityhydrophil
intramolecular
hydrogen
bond
might
result
develop
potent
analogu
fq
fig
chemic
structur
disubstitut
ferrocen
cq
deriv
termin
nitrogen
atom
cq
deriv
bridg
two
cyclopentadienyl
ring
ferrocen
monosubstitut
ferrocen
cq
analogu
correspond
organ
fragment
vitro
antiplasmodi
activ
cqsensit
p
falciparum
strain
cqresist
strain
respect
ic
valu
taken
refer
valu
cq
fq
ic
valu
indic
compound
activ
higher
fq
cq
respect
hand
valu
indic
compound
activ
higher
cq
fq
thiosemicarbazon
tsc
exhibit
potent
antimalari
activ
past
mechan
antimalari
activ
tsc
attribut
reactiv
oxygen
radic
product
due
intrins
metal
eg
iron
coordin
properti
despit
disappoint
activ
tsc
plasmodium
berghei
infect
mice
renew
interest
tsc
sever
new
lead
compound
develop
kill
certain
protozo
parasit
inhibit
cystein
proteas
addit
novel
target
biot
et
al
report
antimalari
activ
chimera
tsc
fq
fig
brei
strain
origin
africa
indochina
gambia
brazil
respect
contribut
molecular
fragment
includ
ferrocen
deriv
without
moieti
organ
compound
analys
observ
compound
show
higher
activ
ferrocenyl
tsc
demonstr
ic
valu
low
micromolar
rang
tabl
interestingli
incorpor
amino
side
chain
compound
respect
compound
led
slight
increas
antimalari
activ
indic
incorpor
basic
amino
group
ad
potenc
facilit
transport
acid
food
vacuol
parasit
howev
low
inhibit
suggest
inhibitori
mechan
may
also
involv
accord
expect
chimera
tsc
fq
analogu
show
best
activ
differ
strain
p
falciparum
besid
rigid
metallocen
compound
deriv
fq
display
better
inhibit
compar
correspond
flexibl
alkyl
analogu
interest
note
compound
show
typic
food
vacuol
abnorm
associ
inhibitor
investig
indic
may
two
differ
mode
action
one
target
anoth
act
independ
howev
specul
compound
preferenti
accumul
food
vacuol
therefor
show
better
parasit
enzym
inhibit
drug
combin
therapi
brought
improv
treatment
malaria
care
antimalari
drug
combin
caus
delay
select
resist
mutant
howev
complic
simpl
drug
combin
therapi
owe
differ
pharmacokinet
combin
drug
thu
bind
activ
pharmacophor
via
coval
linker
seem
good
altern
strategi
bind
two
activ
molecular
fragment
increas
bioavail
dual
molecul
produc
enabl
merg
activ
molecul
independ
mode
action
prevent
emerg
resist
dual
prodrug
strategi
previous
explor
treatment
malaria
link
two
activ
compon
target
thiol
network
heme
detoxif
pathway
malari
parasit
provid
vitro
vivo
proof
concept
molecular
level
coval
linker
known
play
crucial
role
cleavag
linkag
need
occur
specif
condit
target
cell
biot
et
al
document
antimalari
activ
two
seri
fig
b
report
compound
structur
relat
fq
overal
antimalari
screen
physicochem
paramet
partit
coeffici
bhaematin
inhibit
properti
indic
ferrocen
moieti
coval
flank
alkylamin
regardless
lower
antimalari
activ
drug
conjug
comparison
fq
uniqu
mode
action
fq
ferrocenyl
analogu
observ
chavain
cowork
report
two
seri
ferrocen
antimalari
dual
molecul
wherein
fq
analogu
conjug
glutathion
reductas
inhibitor
via
cleavabl
amid
bond
fig
b
target
two
import
pathway
malari
parasit
clone
p
falciparum
dual
molecul
base
fq
analogu
activ
vitro
clone
p
falciparum
ic
valu
nanomolar
rang
nm
nm
respect
howev
slightli
less
activ
parent
fq
analogu
assum
due
cleavag
oxid
metabol
amid
bond
side
chain
fq
deriv
within
digest
vacuol
critic
analysi
research
report
indic
failur
achiev
higher
antimalari
activ
dual
conjug
satisfi
evid
uniqu
mechan
action
fq
ferrocenyl
analogu
obtain
develop
new
potent
fq
derivativesanalogu
continu
goal
research
explor
antimalari
properti
fq
moreov
thirst
develop
new
deriv
also
import
effect
differ
function
group
chemic
moieti
work
develop
rational
fqbase
antimalari
drug
develop
biot
et
al
develop
fq
deriv
fig
chemic
transform
nitrogen
atom
place
quinolin
ring
studi
influenc
basic
lipophil
featur
antimalari
activ
inhibit
bhaematin
format
deriv
screen
twelv
strain
p
falciparum
includ
voll
pa
bre
compound
activ
cq
sever
cqresist
strain
tabl
develop
compound
also
show
better
lipophil
fq
cq
cytosol
vacuolar
ph
indic
simpl
relationship
activ
drug
accumul
inhibit
bhaematin
format
increas
lipophil
fq
deriv
attribut
increas
length
side
chain
overal
result
indic
fact
ferrocen
moieti
need
coval
flank
alkylamin
molecular
structur
deriv
thu
antimalari
activ
suggest
account
subtl
combin
membran
penetr
local
hemetarget
inhibit
hemozoin
format
properti
sever
effort
made
establish
role
ferrocenyl
moieti
antiplasmodi
activ
fq
direct
blacki
cowork
report
structur
analogu
fq
wherein
ferrocenyl
moieti
replac
correspond
rutheniumbas
moieti
fig
ruthenoquin
besid
fq
analogu
differ
aromat
substitu
fig
also
report
interest
observ
ruthenoquin
analogu
demonstr
compar
potenc
fq
tabl
sensit
resist
strain
p
falciparum
suggest
ferrocenyl
fragment
simpli
serv
hydrophob
spacer
group
organosilicon
moieti
incorpor
drug
molecul
order
increas
lipophil
biolog
activ
addit
reduc
toxic
enhanc
drug
therapeut
valu
li
et
al
document
bioavail
featur
vitro
antiplasmodi
activ
carbosilan
congen
fq
heterometal
complex
fig
chloroquinesensit
chloroquineresist
strain
p
falciparum
siliconcontain
congen
prepar
incorpor
organosilicon
motif
later
side
chain
fq
bioavail
studi
indic
moder
solubl
compound
pb
phosphat
buffer
salin
buffer
physiolog
ph
room
temperatur
compound
least
solubl
turbidimetr
solubl
mm
compound
turbidimetr
solubl
mm
best
solubl
properti
bioavail
data
suggest
synthes
ferroquin
deriv
suitabl
vitro
screen
compound
display
high
activ
strain
p
falciparum
tabl
ic
valu
rang
nm
respect
howev
complex
activ
compound
ic
valu
nm
respect
strain
addit
metal
complex
abl
inhibit
format
synthet
hemozoin
critic
analysi
research
report
show
none
deriv
superior
antimalari
activ
comparison
fq
howev
meaning
structureeact
relationship
benefici
effect
evid
cross
resist
could
defin
compound
report
herein
screen
sensit
resist
strain
malari
parasit
result
demonstr
benefit
incorpor
organosilicon
moieti
activ
enhanc
exist
newli
develop
drug
heterobimetal
complex
bifunct
agent
two
activ
metal
centr
capabl
show
interact
biolog
target
present
scenario
wit
grow
interest
design
heterometal
complex
agent
treatment
differ
diseas
two
differ
biolog
activ
metal
incorpor
molecul
usual
improv
activ
due
differ
interact
two
differ
tabl
vitro
activ
ic
valu
nm
differ
strain
p
falciparum
ic
valu
indic
compound
activ
higher
cq
metal
multipl
biolog
target
improv
physicochem
properti
result
heterometal
complex
blacki
et
al
quest
explor
whether
two
metal
centr
molecul
lead
addit
synergist
antagonist
effect
toward
antimalari
activ
report
antimalari
properti
rhodiumand
goldbas
heterobimetal
complex
fig
fq
analogu
cqsensit
cqresist
stain
p
falciparum
author
chemic
structur
fq
analogu
differ
aromat
substitu
also
present
comparison
vitro
antiplasmodi
activ
ruthenoquin
analogu
fq
analogu
cqsensit
chloroquineresist
strain
p
falciparum
ic
valu
indic
compound
activ
higher
fq
observ
coordin
gold
rhodium
increas
efficaci
cq
particularli
cqresist
strain
ferrocenyl
ligand
activ
chloroquinebas
gold
rhodium
complex
resist
strain
overal
observ
complex
second
metal
brought
littl
effect
overal
activ
compound
basic
appear
antagonist
effect
overal
efficaci
complex
second
metal
howev
need
understood
irrespect
fact
gold
rhodium
heterobimetal
complex
unabl
demonstr
addit
synergist
behaviour
possibl
synerg
heterobimetal
system
rule
besid
complex
screen
cqresist
suscept
stain
p
falciparum
strong
conclus
deriv
discuss
articl
explor
sever
fq
deriv
differ
structur
modif
possess
promis
antimalari
properti
basic
purpos
ration
drug
design
use
fq
templat
analogu
obtain
new
synthet
deriv
analogu
better
activ
lower
toxic
therapeut
benefit
comparison
standard
antimalari
like
cq
fq
cours
sever
class
fq
deriv
demonstr
better
antimalari
activ
cq
fq
hydroxyferroquin
deriv
demonstr
better
activ
cq
strain
p
falciparum
three
fq
deriv
compound
display
higher
activ
cq
howev
compound
slightli
activ
cq
four
trioxaferroquin
sever
fold
activ
cq
strain
p
falciparum
howev
three
hydroxyferroquin
deriv
four
trioxaferroquin
display
lower
activ
fq
ferrocenophan
analogu
ferroquin
activ
cq
cqresist
strain
p
falciparum
besid
ferrocenophan
deriv
display
higher
activ
fq
cqresist
strain
best
compound
show
better
activ
cq
fq
cqsensit
analogu
sever
fold
activ
cq
voll
pa
bre
fcm
strain
p
falciparum
howev
none
deriv
activ
fq
interestingli
rutheniumbas
analogu
fq
ruthenoquin
activ
fq
cqresist
strain
p
falciparum
ruthenoquin
analogu
activ
fq
cqsensit
strain
p
falciparum
fq
deriv
show
better
activ
cq
cqsensit
cqresist
strain
wherea
deriv
activ
cq
cqresist
cqsensit
strain
respect
appreci
vitro
antiplasmodi
activ
demonstr
carbosilan
congen
fq
heterometal
complex
compound
exhibit
better
activ
fq
strain
p
falciparum
hand
activ
higher
cq
display
strain
p
falciparum
howev
best
fq
deriv
among
congen
slightli
activ
cq
strain
approxim
activ
fq
plasmodium
strain
overal
discuss
section
indic
posit
move
toward
discoveri
effici
antimalari
agent
use
fq
base
compound
bright
futur
seen
differ
class
fq
deriv
analogu
promis
activ
sever
geograph
divers
strain
p
falciparum
keen
observ
vitro
antimalari
properti
fq
deriv
indic
sever
deriv
demonstr
activ
better
cq
also
fq
case
differ
sensit
resist
strain
p
falciparum
activ
compound
demonstr
better
activ
cq
consider
less
activ
fq
therefor
easi
envisag
develop
deriv
better
activ
fq
also
cq
achiev
far
ration
drug
develop
base
fq
concern
compound
activ
better
cq
strain
p
falciparum
serv
templat
futur
develop
effici
antimalari
strain
p
falciparum
similarli
compound
may
use
develop
potenti
antimalari
strain
p
falciparum
futur
develop
must
includ
vivo
test
compound
compound
deserv
evalu
vivo
experi
treatment
malari
infect
due
cqresist
strain
p
falciparum
ferrocenophan
deriv
repres
interest
exampl
futur
investig
cqresist
strain
compound
demonstr
better
activ
fq
develop
fq
analogu
sever
fold
higher
activ
cq
voll
pa
bre
fcm
strain
indic
compound
potenti
progress
futur
antimalari
p
falciparum
strain
therefor
huge
benefit
develop
compound
new
gener
possibl
agent
treatment
malaria
ruthenoquin
compound
may
suppos
bright
futur
develop
futur
gener
drug
hope
treat
infect
due
cqresist
strain
carbosilan
congen
fq
heterometal
complex
also
demonstr
excit
vitro
antimalari
activ
strain
p
falciparum
compound
class
demonstr
better
activ
fq
cq
two
pathogen
strain
howev
must
mention
best
congen
activ
fq
strain
thu
carbosilan
congen
find
special
place
develop
new
gener
antimalari
antidot
use
fq
templat
compound
may
test
vivo
possibl
effect
sever
strain
p
falciparum
new
effici
antimalari
may
develop
nutshel
sever
fq
deriv
analogu
demonstr
promis
vitro
activ
deserv
attent
investig
vivo
anim
model
besid
excit
templat
chosen
develop
new
effici
deriv
analogu
toxic
one
seriou
issu
import
often
look
keenli
develop
antimalari
drug
drug
toxic
accept
drug
less
harm
diseas
main
toxic
associ
use
cq
sever
itch
skin
often
advers
effect
african
patient
combin
cq
proguanil
good
toler
combin
usual
associ
mouth
ulcer
gastrointestin
problem
treatment
quinin
side
effect
hypoglycaemia
halofantrin
establish
unsuit
widespread
use
human
due
potenti
cardiotox
interestingli
famou
fq
shown
respond
neg
ame
fetax
frog
embryo
teratogenesi
assay
xenopu
test
besid
also
show
neg
result
micronucleu
vitro
vivo
assay
howev
found
weakli
mutagen
genotox
similar
type
experi
hydroxyferroquin
investig
toxic
effect
vero
kidney
epitheli
cell
cell
cultur
minimum
toxic
concentr
compound
vero
cell
mm
respect
fq
show
minimum
toxic
concentr
mm
cell
cultur
seen
compound
similar
toxic
effect
fq
wherea
compound
consider
less
toxic
toxic
investig
indic
compound
view
promis
altern
fq
fq
deriv
report
sala
et
al
investig
toxic
effect
normal
breast
epitheli
cell
cell
compound
lower
toxic
toward
cell
ic
mm
compar
cq
fq
display
toxic
ic
valu
mm
respect
cell
line
compound
toxic
cq
less
toxic
fq
evid
ic
valu
mm
howev
deriv
consider
toxic
fq
cq
toward
cell
result
indic
fact
incorpor
ferrocenyl
moieti
increas
toxic
previous
seen
ferrocenyl
chloroquin
compound
howev
detail
studi
need
determin
toxic
compound
comment
real
candidatur
futur
drug
interestingli
ruthenoquin
toxic
dosag
mm
demonstr
observ
lower
toxic
fq
toxic
dosag
mm
toward
monkey
kidney
cell
cell
select
indic
respect
clear
discuss
section
fq
deriv
exhibit
toxic
effect
toward
normal
cell
deriv
mildli
toxic
exhibit
pronounc
toxic
comparison
cq
fq
howev
limit
studi
avail
subject
investig
need
comment
issu
besid
need
carri
toxic
studi
fq
deriv
vitro
vivo
visual
potenti
compound
antimalari
chemotherapi
enorm
advanc
almost
everi
sphere
scienc
technolog
last
coupl
decad
despit
advanc
treatment
malaria
still
far
doubt
malaria
threat
human
be
world
big
challeng
societi
applic
present
avail
antimalari
drug
limit
due
side
effect
drug
issu
onset
resist
sever
malari
parasit
develop
novel
antimalari
associ
mani
impedi
main
problem
lie
fact
gener
guidelin
avail
could
direct
synthesi
new
activ
antimalari
least
possibl
onset
resist
thu
antimalari
molecul
activ
investig
near
futur
still
mysteri
till
signific
advanc
understand
molecular
aetiolog
malaria
ideal
therapeut
modal
still
miss
view
fact
urgent
speed
develop
new
antimalari
therapeut
potenti
divers
molecul
ligand
metal
complex
fulli
har
design
novel
effici
antimalari
would
benefic
explor
fq
deriv
divers
molecular
featur
topolog
antimalari
besid
target
activ
strategi
may
help
develop
futur
gener
antimalari
abil
overcom
disadvantag
fq
deriv
fq
deriv
obtain
reduc
side
effect
broad
spectrum
activ
onset
drug
resist
modern
theoret
method
densiti
function
theori
molecular
oper
environ
techniqu
high
resolut
electrospray
mass
spectrometri
multinuclear
polar
transfer
nmr
nuclear
magnet
reson
spectroscopi
greatli
help
sure
improv
understand
chemic
biochem
reactiv
drug
might
help
establish
meaning
structureeact
relationship
therefor
chemic
studi
antimalari
physiologicallyrelev
condit
eg
biolog
screen
condit
becom
import
drug
develop
rational
nanotechnolog
faith
far
sever
import
issu
convent
antimalari
chemotherapi
concern
besid
nanotechnolog
expect
help
develop
new
gener
effect
antimalari
therapi
potenti
overcom
biolog
biophys
biomed
barrier
bodi
impos
chemotherapeut
intervent
drug
molecul
trap
within
nanostructur
framework
protect
degrad
blood
system
allow
safe
deliveri
target
site
nanodrug
exhibit
least
side
effect
toward
normal
cell
potenti
cross
cancer
cell
barrier
easili
besid
drug
evad
unproduct
properti
convent
antimalari
thu
would
consider
interest
antimalari
trap
nano
cage
might
avoid
poor
bioavail
ensur
select
specif
fast
action
trap
drug
nano
ident
fq
deriv
may
expect
effect
replac
convent
counterpart
report
indic
synergist
effect
sever
malari
case
use
new
antimalari
combin
establish
drug
therefor
combin
therapi
need
explor
order
get
novel
drug
combin
near
futur
besid
import
establish
dosag
ratio
combin
drug
particular
formul
present
scenario
softwar
simul
programm
use
estim
drug
therapeut
effici
even
actual
synthes
thu
simul
drug
good
bioavail
maximum
solubl
remark
less
side
effect
higher
effici
need
design
develop
malari
infect
gener
involv
multipl
complex
biochem
pathway
therefor
success
treatment
depend
pharmaceut
intervent
multipl
pathway
sometim
combin
differ
drug
henc
envisag
develop
fqbase
design
multipl
ligand
may
act
multipl
biolog
target
quit
help
erad
malaria
view
discuss
section
understand
molecular
mechan
inhibit
malari
sporozoit
fq
deriv
forese
design
develop
new
fq
analogu
along
develop
nano
counterpart
fq
deriv
realli
great
see
work
medicin
chemist
need
develop
safe
effect
fq
deriv
either
nano
regim
normal
size
rang
treatment
malaria
briefli
futur
fqbase
scafold
quit
bright
treatment
malaria
ineffici
quinin
deriv
malari
parasit
particularli
resist
strain
p
falciparum
stimul
develop
structur
relev
molecul
treatment
malaria
cours
fq
show
potenti
candid
treatment
malaria
howev
quest
develop
effect
antimalari
still
continu
recent
much
research
carri
world
develop
fq
deriv
antimalari
agent
promis
result
obtain
fq
deriv
display
sever
fold
higher
activ
comparison
cq
howev
research
still
need
carri
explor
new
molecul
base
fq
scafold
antimalari
agent
fq
deriv
analogu
report
better
activ
cq
fq
plethora
malari
parasit
need
investig
toxic
effect
vitro
vivo
may
help
us
realiz
real
potenti
antimalari
agent
clinic
interest
malaria
greatli
affect
econom
statu
particularli
develop
nation
therefor
need
erad
soon
possibl
direct
explor
antimalari
potenti
fq
deriv
along
mechan
action
ray
hope
definit
futur
fq
deriv
quit
bright
sinc
step
right
direct
toward
erad
malaria
conflict
interest
declar
